Vistin Pharma ASALTS:0RAM 77 EV-to-EBITDA is 6.79 as of Jul. 06, 2026, which is 20% below its 10-year median of 8.46. GuruFocus rates LTS:0RAM with a GF Score™ of 77/100 and a GF Value™ of kr25.61 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 739 Drug Manufacturers companies, Vistin Pharma ASA ranks better than 78.89% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vistin Pharma ASA's enterprise value is kr888.8 Mil.
Vistin Pharma ASA's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr131.0 Mil. Therefore, Vistin Pharma ASA's EV-to-EBITDA for today is 6.79.
The historical rank and industry rank for Vistin Pharma ASA's EV-to-EBITDA or its related term are showing as below:
LTS:0RAM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -463.06 Med: 8.46 Max: 108.63
Current: 6.79
During the past 13 years, the highest EV-to-EBITDA of Vistin Pharma ASA was 108.63. The lowest was -463.06. And the median was 8.46.
LTS:0RAM's EV-to-EBITDA is ranked better than 78.89% of 739
companies
in the Drug Manufacturers industry
Industry Median: 12.85
vs LTS:0RAM: 6.79
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vistin Pharma ASA's PE Ratio (TTM) for today is calculated as:
Vistin Pharma ASA's share price for today is kr20.70.
Vistin Pharma ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.680.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Vistin Pharma ASA's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RAM vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's EV-to-EBITDA falls into.
Vistin Pharma ASA's current Enterprise Value is kr888.8 Mil.
Vistin Pharma ASA's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr131.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistin Pharma ASA (LTS:0RAM) has a EV-to-EBITDA of 6.79 as of Jul. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vistin Pharma ASA. This is 20% below median its historical median of 8.46. According to the industry distribution chart, Vistin Pharma ASA ranks #156 out of 739 companies in the Drug Manufacturers industry, placing it in the top 21.1%.
Is Vistin Pharma ASA's EV-to-EBITDA too high?
Vistin Pharma ASA's current EV-to-EBITDA of 6.79 is 20% below median its 10-year median of 8.46. The Drug Manufacturers industry median EV-to-EBITDA is 12.85. Vistin Pharma ASA's value of 6.79 is 47.2% below this industry median. Based on the distribution chart, Vistin Pharma ASA ranks #156 out of 739 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vistin Pharma ASA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #156 out of 739 companies for EV-to-EBITDA. This places Vistin Pharma ASA in the top 21% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 12.85. Vistin Pharma ASA's value of 6.79 is 47.2% below this benchmark. While the company's 10-year median is 8.46 vs. the industry median of 12.85, Vistin Pharma ASA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.85, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistin Pharma ASA's current EV-to-EBITDA of 6.79 is 47.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vistin Pharma ASA. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current EV-to-EBITDA is 6.79, which is 20% below median its own 10-year median of 8.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.61, compared to a current price of kr20.70 — trading 19.2% below its estimated fair value. The current EV-to-EBITDA is 6.79, which is 20% below median its 10-year median of 8.46 and 47.2% below the Drug Manufacturers industry median of 12.85. Vistin Pharma ASA's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current EV-to-EBITDA is 6.79 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr20.70 is trading 19.2% below its estimated GF Value™ of kr25.61.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for LTS:0RAM:
EV-to-EBITDA: 6.79 (20% below median its 10-year median of 8.46)
GF Value™: kr25.61 vs. price of kr20.70 (19.2% below fair value)
Industry Position: 47.2% below the Drug Manufacturers median (#156 of 739)
No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
77GF Score
Get the complete analysis for LTS:0RAM
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAM has been successfully added to your 
